

LEMTRADA (alemtuzumab)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 17 years of age and older

Diagnosis

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease

AND ALL of the following:

- Inadequate response to at least two drugs indicated for the treatment of MS
- 2. Prescriber and patient must be enrolled in Lemtrada REMS program

AND NONE of the following:

- 1. Clinically isolated syndrome
- 2. Co-infection with HIV
- 3. Used in combination with another MS disease modifying agent
- 4. Used concurrently with live vaccines

Prior - Approval Limits

Duration 2 years

Prior - Approval Renewal Requirements

Age 17 years of age and older

Diagnosis

Patient must have the following:

Relapsing Multiple Sclerosis (MS), including relapsing-remitting disease and active secondary progressive disease

AND ALL of the following:

Prescriber and patient must be enrolled in Lemtrada REMS program



LEMTRADA

Federal Employee Program. (alemtuzumab)

AND NONE of the following:

- 1. Clinically isolated syndrome
- 2. Co-infection with HIV
- 3. Used in combination with another MS disease modifying agent
- 4. Used concurrently with live vaccines

Prior - Approval Renewal Limits

Same as above